

# Ryszard Międzybrodzki

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1139233/publications.pdf>

Version: 2024-02-01

66  
papers

3,310  
citations

159585

30  
h-index

155660

55  
g-index

69  
all docs

69  
docs citations

69  
times ranked

2764  
citing authors

#	ARTICLE	IF	CITATIONS
1	Phage therapy of wound-associated infections. <i>Folia Microbiologica</i> , 2022, 67, 193-201.	2.3	15
2	The contribution of phage therapy to medical knowledge. <i>Journal of Global Antimicrobial Resistance</i> , 2022, 28, 238-240.	2.2	6
3	Bacteriophages and antibiotic interactions in clinical practice: what we have learned so far. <i>Journal of Biomedical Science</i> , 2022, 29, 23.	7.0	39
4	A Thorough Synthesis of Phage Therapy Unit Activity in Polandâ€™s History, Milestones and International Recognition. <i>Viruses</i> , 2022, 14, 1170.	3.3	11
5	Treatment of recurrent urinary tract infections in a 60â€™yearâ€™old kidney transplant recipient. The use of phage therapy. <i>Transplant Infectious Disease</i> , 2021, 23, e13391.	1.7	42
6	Low Immunogenicity of Intravesical Phage Therapy for Urogenitary Tract Infections. <i>Antibiotics</i> , 2021, 10, 627.	3.7	9
7	Immune Response to Therapeutic Staphylococcal Bacteriophages in Mammals: Kinetics of Induction, Immunogenic Structural Proteins, Natural and Induced Antibodies. <i>Frontiers in Immunology</i> , 2021, 12, 639570.	4.8	19
8	Potential for Phages in the Treatment of Bacterial Sexually Transmitted Infections. <i>Antibiotics</i> , 2021, 10, 1030.	3.7	8
9	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. , 2021, , 921-951.		8
10	Therapeutic Perspectives and Mechanistic Insights of Phage Therapy in Allotransplantation. <i>Transplantation</i> , 2021, 105, 1449-1458.	1.0	13
11	BronisÅ™awa Fejgin (1883â€™1943): Forgotten Important Contributor to International Microbiology and Phage Therapy. <i>Antibiotics</i> , 2021, 10, 1353.	3.7	2
12	Phage therapy: Current status and perspectives. <i>Medicinal Research Reviews</i> , 2020, 40, 459-463.	10.5	102
13	Sepsis, Phages, and COVID-19. <i>Pathogens</i> , 2020, 9, 844.	2.8	6
14	Phage Prevalence in the Human Urinary Tractâ€™ Current Knowledge and Therapeutic Implications. <i>Microorganisms</i> , 2020, 8, 1802.	3.6	16
15	Phage Therapy: Towards a Successful Clinical Trial. <i>Antibiotics</i> , 2020, 9, 827.	3.7	59
16	Phages in the fight against COVID-19?. <i>Future Microbiology</i> , 2020, 15, 1095-1100.	2.0	26
17	The Rationale for Using Bacteriophage to Treat and Prevent Periprosthetic Joint Infections. <i>Frontiers in Microbiology</i> , 2020, 11, 591021.	3.5	9
18	Phage Therapy in Poland â€™ a Centennial Journey to the First Ethically Approved Treatment Facility in Europe. <i>Frontiers in Microbiology</i> , 2020, 11, 1056.	3.5	44

#	ARTICLE	IF	CITATIONS
19	Natural and Induced Antibodies Against Phages in Humans: Induction Kinetics and Immunogenicity for Structural Proteins of PB1-Related Phages. <i>Phage</i> , 2020, 1, 91-99.	1.7	12
20	Bacteriophage Interactions With Epithelial Cells: Therapeutic Implications. <i>Frontiers in Microbiology</i> , 2020, 11, 631161.	3.5	14
21	The effects of T4 and A5/80 phages on the expression of immunologically important genes in differentiated Caco-2 cells*. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2020, 74, 371-376.	0.1	5
22	Inhibitory Effects of Bacteriophage Preparations on Adenoviral Replication. <i>Intervirolgy</i> , 2019, 62, 37-44.	2.8	7
23	The fall and rise of phage therapy in modern medicine. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 1115-1117.	3.1	19
24	Factors determining phage stability/activity: challenges in practical phage application. <i>Expert Review of Anti-Infective Therapy</i> , 2019, 17, 583-606.	4.4	82
25	Phage-specific diverse effects of bacterial viruses on the immune system. <i>Future Microbiology</i> , 2019, 14, 1171-1174.	2.0	22
26	Phage Therapy in Orthopaedic Implant-Associated Infections. , 2019, , 189-211.		5
27	The effects of bacteriophages on the expression of genes involved in antimicrobial immunity*. <i>Postepy Higieny I Medycyny Doswiadczalnej</i> , 2019, 73, 414-420.	0.1	7
28	Humoral Immune Response to Phage-Based Therapeutics. , 2019, , 123-143.		3
29	Phage therapy in allergic disorders?. <i>Experimental Biology and Medicine</i> , 2018, 243, 534-537.	2.4	13
30	Bacteriophages targeting intestinal epithelial cells: a potential novel form of immunotherapy. <i>Cellular and Molecular Life Sciences</i> , 2018, 75, 589-595.	5.4	24
31	Use of a Regression Model to Study Host-Genomic Determinants of Phage Susceptibility in MRSA. <i>Antibiotics</i> , 2018, 7, 9.	3.7	5
32	“Phage Transplantation in Allotransplantation” Possible Treatment in Graft-Versus-Host Disease?. <i>Frontiers in Immunology</i> , 2018, 9, 941.	4.8	8
33	Phage Therapy: Beyond Antibacterial Action. <i>Frontiers in Medicine</i> , 2018, 5, 146.	2.6	27
34	Perspectives of Phage“Eukaryotic Cell Interactions to Control Epstein“Barr Virus Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 630.	3.5	13
35	Phage Therapy in Prostatitis: Recent Prospects. <i>Frontiers in Microbiology</i> , 2018, 9, 1434.	3.5	18
36	Phage Therapy: What Have We Learned?. <i>Viruses</i> , 2018, 10, 288.	3.3	101

#	ARTICLE	IF	CITATIONS
37	Perspectives of Phage Therapy in Non-bacterial Infections. <i>Frontiers in Microbiology</i> , 2018, 9, 3306.	3.5	49
38	Current Updates from the Long-Standing Phage Research Centers in Georgia, Poland, and Russia. , 2018, , 1-31.		13
39	Phages and immunomodulation. <i>Future Microbiology</i> , 2017, 12, 905-914.	2.0	117
40	Can phage therapy solve the problem of recalcitrant chronic rhinosinusitis?. <i>Future Microbiology</i> , 2017, 12, 1427-1442.	2.0	8
41	Antiphage activity of sera during phage therapy in relation to its outcome. <i>Future Microbiology</i> , 2017, 12, 109-117.	2.0	71
42	A3R Phage and Staphylococcus aureus Lysate Do Not Induce Neutrophil Degranulation. <i>Viruses</i> , 2017, 9, 36.	3.3	20
43	Phage-Phagocyte Interactions and Their Implications for Phage Application as Therapeutics. <i>Viruses</i> , 2017, 9, 150.	3.3	62
44	The Potential of Phage Therapy in Sepsis. <i>Frontiers in Immunology</i> , 2017, 8, 1783.	4.8	35
45	Prospects of Phage Application in the Treatment of Acne Caused by <i>Propionibacterium acnes</i> . <i>Frontiers in Microbiology</i> , 2017, 8, 164.	3.5	30
46	Means to Facilitate the Overcoming of Gastric Juice Barrier by a Therapeutic Staphylococcal Bacteriophage A5/80. <i>Frontiers in Microbiology</i> , 2017, 08, 467.	3.5	50
47	<i>In Vivo</i> Studies on the Influence of Bacteriophage Preparations on the Autoimmune Inflammatory Process. <i>BioMed Research International</i> , 2017, 2017, 1-9.	1.9	39
48	Phage Therapy: Combating Infections with Potential for Evolving from Merely a Treatment for Complications to Targeting Diseases. <i>Frontiers in Microbiology</i> , 2016, 7, 1515.	3.5	120
49	Antibody Production in Response to Staphylococcal MS-1 Phage Cocktail in Patients Undergoing Phage Therapy. <i>Frontiers in Microbiology</i> , 2016, 7, 1681.	3.5	92
50	The Effect of Bacteriophage Preparations on Intracellular Killing of Bacteria by Phagocytes. <i>Journal of Immunology Research</i> , 2015, 2015, 1-13.	2.2	39
51	Phages targeting infected tissues: novel approach to phage therapy. <i>Future Microbiology</i> , 2015, 10, 199-204.	2.0	40
52	Functional Regeneration of Supraspinal Connections in a Patient with Transected Spinal Cord following Transplantation of Bulbar Olfactory Ensheathing Cells with Peripheral Nerve Bridging. <i>Cell Transplantation</i> , 2014, 23, 1631-1655.	2.5	199
53	Phage Neutralization by Sera of Patients Receiving Phage Therapy. <i>Viral Immunology</i> , 2014, 27, 295-304.	1.3	179
54	Transplantation of Autologous Olfactory Ensheathing Cells in Complete Human Spinal Cord Injury. <i>Cell Transplantation</i> , 2013, 22, 1591-1612.	2.5	238

#	ARTICLE	IF	CITATIONS
55	Influence of Bacteriophage Preparations on Intracellular Killing of Bacteria by Human Phagocytes <i>in Vitro</i> . <i>Viral Immunology</i> , 2013, 26, 150-162.	1.3	12
56	Phage as a Modulator of Immune Responses. <i>Advances in Virus Research</i> , 2012, 83, 41-71.	2.1	206
57	Clinical Aspects of Phage Therapy. <i>Advances in Virus Research</i> , 2012, 83, 73-121.	2.1	274
58	Potential of Bacteriophages and Their Lysins in the Treatment of MRSA. <i>BioDrugs</i> , 2011, 25, 347-355.	4.6	23
59	The perspectives of the application of phage therapy in chronic bacterial prostatitis. <i>FEMS Immunology and Medical Microbiology</i> , 2010, 60, 99-112.	2.7	51
60	A retrospective analysis of changes in inflammatory markers in patients treated with bacterial viruses. <i>Clinical and Experimental Medicine</i> , 2009, 9, 303-312.	3.6	53
61	Bacteriophage preparation inhibition of reactive oxygen species generation by endotoxin-stimulated polymorphonuclear leukocytes. <i>Virus Research</i> , 2008, 131, 233-242.	2.2	78
62	Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. <i>Postepy Higieny i Medycyny Doswiadczonej</i> , 2007, 61, 461-5.	0.1	43
63	Bacteriophage translocation. <i>FEMS Immunology and Medical Microbiology</i> , 2006, 46, 313-319.	2.7	192
64	Effects of bacteriophages on free radical production and phagocytic functions. <i>Medical Microbiology and Immunology</i> , 2006, 195, 143-150.	4.8	81
65	The olfactory bulb and olfactory mucosa obtained from human cadaver donors as a source of olfactory ensheathing cells. <i>Glia</i> , 2006, 54, 557-565.	4.9	33
66	Bacterial viruses against viruses pathogenic for man?. <i>Virus Research</i> , 2005, 110, 1-8.	2.2	38